Status:
RECRUITING
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Lead Sponsor:
AstraZeneca
Conditions:
Cardiovascular Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in ...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
June 4 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 26 2029
Estimated Enrollment :
15100 Patients enrolled
Trial Details
Trial ID
NCT07000357
Start Date
June 4 2025
End Date
October 26 2029
Last Update
February 27 2026
Active Locations (1227)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States, 35205
2
Research Site
Fairhope, Alabama, United States, 36532
3
Research Site
Foley, Alabama, United States, 36535
4
Research Site
Huntsville, Alabama, United States, 35801